Literature DB >> 32320558

Finally, a Successful Randomized Trial for GVHD.

Nelson Chao1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32320558     DOI： 10.1056/NEJMe2003331

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease.

Authors:  Robert Zeiser; Gérard Socié
Journal:  Blood Adv       Date:  2020-08-11

2.  Unmasking viral sequences by metagenomic next-generation sequencing in adult human blood samples during steroid-refractory/dependent graft-versus-host disease.

Authors:  L Kaiser; D L Vu; M C Zanella; S Cordey; F Laubscher; M Docquier; G Vieille; C Van Delden; V Braunersreuther; Mc Kee Ta; J A Lobrinus; S Masouridi-Levrat; Y Chalandon
Journal:  Microbiome       Date:  2021-01-24       Impact factor: 14.650

3.  Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies.

Authors:  Yingxin Zhao; Peng Chen; Liping Dou; Fei Li; Meng Li; Lingmin Xu; Jing Chen; Mingyu Jia; Sai Huang; Nan Wang; Songhua Luan; Jinling Yang; Nan Bai; Daihong Liu
Journal:  Drug Des Devel Ther       Date:  2022-03-25       Impact factor: 4.162
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.